# OnCo record cbx-250 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cbx-250/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cbx-250" ;
  schema:name "CBX-250"@en ;
  schema:description "CBX-250 is an experimental TCR-mimetic T cell engager from Crossbow Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia, higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia and other cancers."@en ;
  schema:url <https://onco.cc/drugs/cbx-250/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.crossbowtx.com/press-release-09-16-25>, <https://www.crossbowtx.com/>, <https://clinicaltrials.gov/study/NCT06994676>, <https://clinicaltrials.gov/search?intr=CBX-250> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "TCR-mimetic T cell engager (T-Bolt)" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/>, <https://onco.cc/cancers/cmml/> ;
  onco:companies <https://onco.cc/companies/crossbow-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06994676/> .